TUDOFOVIR 300mg tablet

TUDOFOVIR 300mg tablet is an antiviral medicine with Tenofovir disoproxil fumarate as an active ingredient. It is used in the treatment of chronic hepatitis B virus (HBV) infection and also HIV infection in combination with other anti-HIV drugs. It works by preventing the multiplication of viruses in human cells to stop the production of new viruses and clears up the infection from the body. It should be taken in dose and duration as advice by the doctor. Don't take more than the recommended dose.

​

• Hepatitis B virus (HBV) infection
• Treatment of HIV infection

Every medicine has some side effects that typically manage on their own as your body gets used to the medicine, but some people may experience severe side effects rarely. In that case, the patient should contact the doctor immediately.

Some common side effects of TUDOFOVIR 300mg tablet include:

• Diarrhea
• Nausea
• Rash
• Weakness
• Vomiting
• Fatigue
• Abdominal pain
• Increased transaminase level in blood
• Decreased phosphate level in blood
• Pain
• Dizziness
• Depression
• Insomnia (difficulty in sleeping)
• Fever
• Itching

Contact your healthcare provider if you face any unusual or persistent side effects.

• The dosage and treatment duration of the TUDOFOVIR 300mg tablet are decided by the doctor according overall patient's health.
• This tablet should be taken with or without food, but at the fix time every day to get effective results. Don't miss a dose or overdose on the medicine.
  
  

• TUDOFOVIR 300mg tablet is an antiviral medicine with Tenofovir disoproxil fumarate as an active ingredient.
• It works by preventing the multiplication of viruses in human cells to stop the production of new viruses and clears up the infection from the body.
  
  

• Nelson, M. R., Katlama, C., Montaner, J. S., Cooper, D. A., Gazzard, B., Clotet, B. ... & Rooney, J. F. (2007). The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. Aids, 21(10), 1273-1281.
• Hill, A., Hughes, S. L., Gotham, D., & Pozniak, A. L. (2018). Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? Journal of virus eradication, 4(2), 72-79.
• De Clercq, E. (2016). Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochemical pharmacology, 119, 1-7.
• Kearney, B. P., Flaherty, J. F., & Shah, J. (2004). Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clinical pharmacokinetics, 43(9), 595-612.
• Chapman, T. M., McGavin, J. K., & Noble, S. (2003). Tenofovir disoproxil fumarate. Drugs, 63(15), 1597-1608.
• Gallant, J. E., & Deresinski, S. (2003). Tenofovir disoproxil fumarate. Clinical Infectious Diseases, 37(7), 944-950.